Human Umbilical Cord Blood as a Source of Transplantable Hematopoietic Stem and Progenitor Cells

He, Ben; Cooper, Stephanie; Yöder, Mervin C.; Hangoc, Giao

doi:10.1007/978-3-642-76912-2_15

Cited by 27 publications

(29 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There has been little or no GVHD detected in children receiving HLA-matched or one antigen mismatched sibling cord blood, 2,3,7,16,22 and results using unrelated CB have been similar. 4,5,16 There is evidence that immune cells from CB react differently to those in adults.…”

Section: Immune Cells In Cord Bloodmentioning

confidence: 82%

“…1,7 A common approach to assess the quality of stem cell grafts relies on methylcellulose-based colony assays for lineage-committed hematopoietic progenitor cells as colony-forming units granulocyte/macrophage (CFU-GM). 7,8 Besides the different culture systems immunofluorescence and flow cytometry can be regarded as a reliable and rapid method for detection of early stem/progenitor cells. The CD34 antigen is of particular interest because it represents the only cell-surface antigen identified by monoclonal antibodies (MoAb), whose expression within the hematopoietic system is restricted to primitive progenitor cells of all lineages.…”

Section: Quantity and Quality Of Immature Hematopoietic Stem Cells Frmentioning

confidence: 99%

See 1 more Smart Citation

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells

Pálóczi

1999

Leukemia

View full text Add to dashboard Cite

Section: Immune Cells In Cord Bloodmentioning

confidence: 82%

Section: Quantity and Quality Of Immature Hematopoietic Stem Cells Frmentioning

confidence: 99%

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells

Pálóczi

1999

Leukemia

View full text Add to dashboard Cite

“…7-9,13 However, major concerns viability. 1,12,14 We have reported a recovery ranging from have been related to the low total number of progenitor 80 to 87% for HPP-CFC, CFU-GEMM, BFU-E and CFUcells obtained by a single collection; concerns are even GM, in the case of unseparated cells, and ranging from 82 higher when the recipient could be an adult patient. Thereto 91% for LTC-IC, CFU-GEMM, BFU-E and CFU-GM, fore, there is considerable interest in attempting to underin the case of MNC cells.…”

Section: 19mentioning

confidence: 97%

“…[1][2][3][4] Therefore, UCB has cedures must be pursued. It has been reported that cryobeen used as a source of hematopoietic progenitor cells for preservation of UCB samples as whole and more recently clinical transplantation, and is proving to be an acceptable separated blood has minimal effects on cell recovery and potential alternative to BM.…”

Section: 19mentioning

confidence: 99%

Clonogenic capacity andex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation

Almici

Carlo‐Stella

Wagner

et al. 1997

Bone Marrow Transplant

View full text Add to dashboard Cite

SummaryFetal blood collected immediately after delivery has been was the aim of this study to evaluate whether cryopreshown to contain hematopoietic progenitor cells at similar servation procedures might heavily impair the clonoor higher frequency than those in bone marrow (BM).1 genic capacity, the feasibility of CD34 ؉ selection and the Therefore, umbilical cord blood (UCB), which is normally ex vivo expansion potential of UCB progenitor cells.discarded, has been evaluated as a source of UCB samples were collected and cryopreserved as stem/progenitor cells 2-4 that can easily be collected at delivunseparated (n ‫؍‬ 21) or mononuclear (MNC) cells (n ery without any danger or inconvenience to the donor. 5,6‫؍‬ 15) within 12 h from delivery, and evaluated for Recently, UCB has been used as a source of hematopoietic viability, immunophenotype, cell and progenitor numstem cells for clinical transplantation, and is proving to be bers after a minimum stay in liquid nitrogen of 6 an acceptable alternative to BM. 7-9 Several studies have months (range 6-14 months). Viability was always demonstrated that UCB contains similar or higher pro-Ͼ97% and no statistically significant difference was portions of primitive hematopoietic progenitor cells as detected by flow cytometric analysis. Clonogenic recovcompared to adult BM 2,4 and therefore the lower number ery from unseparated cells was 80-87% for HPP-CFC, of nucleated cells, present in a single collection, might be CFU-GEMM, BFU-E and CFU-GM, and from MNC compensated by a significantly higher proportion of cells ranged from 82 to 91% for LTC-IC, CFU-GEMM, primitive cells. More recently, highly purified BFU-E and CFU-GM. CD34؉ selection (n ‫؍‬ 8) was per-CD34 capacity has made UCB-derived progenitor cells ideal cansignificant difference was detected in CFC fold-expandidates for experimental programs involving gene transfer sion for fresh or cryopreserved MNC cells and for and ex vivo stem cell expansion. Since several programs CD34 ؉ cells, either selected and cultured from fresh or throughout Europe and the USA are currently evaluating cryopreserved MNC cells. In conclusion we can state the feasibility of large-scale UCB banking for unrelated that UCB is a potential source of primitive progenitor transplants 5,12,13 cytokine-mediated ex vivo expansion of cells that can be cryopreserved unmanipulated or after UCB hematopoietic progenitor cells might increase the physical separation without major losses in clonogenic number of progenitor cells to be transplanted and facilitate capacity and immunophenotypic composition. Moreengraftment in adult patients. Therefore, it was the aim of our study to investigate whether cryopreservation can affect the clonogenic capacity, the immunophenotype, the feasi- potential of UCB progenitor cells.

show abstract

“…Furthermore, the potential for effective antileukemia activity of CB grafts was in doubt because of proven immunological naivety of fetal cells (9)(10)(11)(12). Clinical outcomes of CB transplantation, however, did not support these concerns.…”

mentioning

confidence: 99%

Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation

Rood

Scaradavou

Stevens

2012

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

During pregnancy women can develop B-and T-cell immunity against the inherited paternal antigens (IPAs) of the fetus, such as HLA, peptides of minor histocompatibilty antigens, and possibly oncofetal antigens. The biological and pathological role of these pregnancy-induced immunological events is only understood in part. However, anti-IPA immunity in the mother persists for many decades after delivery and may reduce relapse in offspring with leukemia after HLA-haploidentical transplantation of maternal hematopoietic stem cells (HSC). We hypothesized that maternal anti-IPA immune elements cross the placenta and might confer a potent graft-versusleukemia effect when cord blood (CB) is used in unrelated HSC transplantation. In a retrospective study of single-unit CB recipients with all grafts provided by the New York Blood Center, we show that patients with acute myeloid or lymphoblastic leukemia (n = 845) who shared one or more HLA-A, -B, or -DRB1 antigens with their CB donor's IPAs had a significant decrease in leukemic relapse posttransplantation [hazard ratio (HR) = 0.38, P < 0.001] compared with those that did not. Remarkably, relapse reduction in patients receiving CB with one HLA mismatch (HR = 0.15, P < 0.001) was not associated with an increased risk of severe acute graft-versus-host disease (HR = 1.43, P = 0.730). Our findings may explain the unexpected low relapse rate after CB transplantation, open new avenues in the study of leukemic relapse after HSC transplantation (possibly of malignancies in general), and have practical implications for CB unit selection.cord blood stem cell transplantation | birth order

show abstract

Human Umbilical Cord Blood as a Source of Transplantable Hematopoietic Stem and Progenitor Cells

Cited by 27 publications

References 31 publications

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells

Immunophenotypic and functional characterization of human umbilical cord blood mononuclear cells

Clonogenic capacity andex vivo expansion potential of umbilical cord blood progenitor cells are not impaired by cryopreservation

Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation

Contact Info

Product

Resources

About